Trials / Withdrawn
WithdrawnNCT05409378
HLT® Meridian® TAVR Valve System Early Feasibility Study for Aortic Regurgitation
- Status
- Withdrawn
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- HLT Inc. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and performance of The Meridian® TAVR Valve in patients with severe aortic regurgitation who present at high risk for aortic valve replacement surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | The HLT® Meridian® TAVR Valve (Meridian® with TriVentTM Anticalcification Treatment Valve and Pathfinder® Delivery System) | Aortic valve replacement with the HLT Meridian TAVR Valve to treat aortic regurgitation |
Timeline
- Start date
- 2022-07-08
- Primary completion
- 2023-01-20
- Completion
- 2023-01-20
- First posted
- 2022-06-08
- Last updated
- 2023-05-31
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT05409378. Inclusion in this directory is not an endorsement.